190 related articles for article (PubMed ID: 15120636)
1. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation.
Yuill KH; Borg JJ; Ridley JM; Milnes JT; Witchel HJ; Paul AA; Kozlowski RZ; Hancox JC
Biochem Biophys Res Commun; 2004 May; 318(2):556-61. PubMed ID: 15120636
[TBL] [Abstract][Full Text] [Related]
2. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
Paulussen AD; Raes A; Jongbloed RJ; Gilissen RA; Wilde AA; Snyders DJ; Smeets HJ; Aerssens J
Cardiovasc Res; 2005 Aug; 67(3):467-75. PubMed ID: 15958262
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.
Thomas D; Gut B; Karsai S; Wimmer AB; Wu K; Wendt-Nordahl G; Zhang W; Kathöfer S; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jul; 368(1):41-8. PubMed ID: 12827215
[TBL] [Abstract][Full Text] [Related]
4. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
5. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes.
Liu XK; Katchman A; Ebert SN; Woosley RL
J Pharmacol Exp Ther; 1998 Dec; 287(3):877-83. PubMed ID: 9864267
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
Hansen RS; Olesen SP; Rønn LC; Grunnet M
J Cardiovasc Pharmacol; 2008 Jul; 52(1):35-41. PubMed ID: 18594476
[TBL] [Abstract][Full Text] [Related]
8. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
9. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
10. Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Vigneault P; Bourgault S; Kaddar N; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
Eur J Pharmacol; 2012 Apr; 681(1-3):68-74. PubMed ID: 22366430
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
Choi SY; Koh YS; Jo SH
J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
[TBL] [Abstract][Full Text] [Related]
12. Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.
Crumb WJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):261-4. PubMed ID: 10604956
[TBL] [Abstract][Full Text] [Related]
13. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
[TBL] [Abstract][Full Text] [Related]
14. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
Ponce-Balbuena D; López-Izquierdo A; Ferrer T; Rodríguez-Menchaca AA; Aréchiga-Figueroa IA; Sánchez-Chapula JA
J Pharmacol Exp Ther; 2009 Nov; 331(2):563-73. PubMed ID: 19654266
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of arsenic-induced prolongation of cardiac repolarization.
Ficker E; Kuryshev YA; Dennis AT; Obejero-Paz C; Wang L; Hawryluk P; Wible BA; Brown AM
Mol Pharmacol; 2004 Jul; 66(1):33-44. PubMed ID: 15213294
[TBL] [Abstract][Full Text] [Related]
19. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
20. Inactivation block of the HERG human cardiac K+ channels by RP58866.
Wang H; Shi H; Wang Z
Br J Pharmacol; 1999 Aug; 127(8):1899-907. PubMed ID: 10482922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
